Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Michael B. Andrews's publication output changed over time?
ScholarIQpublication output · 1991–2026
Output grew0% over the shown period — from 1 works in 1991 to 1 in 2026.
1
1
2
5
1
19912005202420252026
What are the most-cited papers on Michael B. Andrews?
ScholarIQmost cited works
Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer.
John D. Hainsworth, Michael B. Andrews, David H. Johnson, Filippo Greco
Journal of Clinical Oncology. 199154 Citations
Rituximab Plus Short-Duration Chemotherapy As First-Line Treatment for Follicular Non-Hodgkin’s Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network
John D. Hainsworth, Sharlene Litchy, Lisa H. Morrissey, Michael B. Andrews, Manuel Grimaldi, Matthew J. McCarty, F. Anthony Greco
Journal of Clinical Oncology. 200545 Citations
Gastroparesis treatment options metoclopramide and prucalopride: analysis of the FDA Adverse Event Reporting System (FAERS) database
Michael B. Andrews, Douglas G. Adler
Expert Review of Gastroenterology & Hepatology. 20244 Citations
Safety of the contrast enhancement agent sulfur hexafluoride in ultrasound: Analysis of the Federal Drug Administration Adverse Event Reporting System database
Courtney Walker, Michael B. Andrews, Douglas G. Adler
Endoscopic Ultrasound. 20243 CitationsOPEN ACCESS
Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implications
Praneeth Kudaravalli, Michael B. Andrews, Douglas G. Adler
Expert Opinion on Drug Safety. 20253 Citations
Related on ScholarIQ
Virginia Commonwealth University
Institution
Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer.
Paper
Rituximab Plus Short-Duration Chemotherapy As First-Line Treatment for Follicular Non-Hodgkin’s Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network
Paper
Gastroparesis treatment options metoclopramide and prucalopride: analysis of the FDA Adverse Event Reporting System (FAERS) database
Paper
Safety of the contrast enhancement agent sulfur hexafluoride in ultrasound: Analysis of the Federal Drug Administration Adverse Event Reporting System database
Paper
Comprehensive analysis of adverse drug reactions associated with teduglutide: post-marketing insights and safety implications
Paper